Close Menu

In PLoS One this week, MIT researchers say they've developed the first ever broad-spectrum antiviral therapeutic. Instead of taking a pathogen-specific approach to developing antivirals, the team has created a new approach, called Double-Stranded RNA Activated Caspase Oligomerizer, or DRACO, which selectively induces apoptosis in cells that contain viral dsRNA, and kills infected cells without harming normal cells.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.